UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 19.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,391 shares of the company's stock after acquiring an additional 22,931 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.27% of PROCEPT BioRobotics worth $11,224,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Thematics Asset Management acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth $46,000. Signaturefd LLC grew its stake in PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after buying an additional 145 shares during the last quarter. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics during the 4th quarter worth $58,000. Arcadia Investment Management Corp MI acquired a new position in PROCEPT BioRobotics during the 4th quarter valued at about $64,000. Finally, KBC Group NV raised its stake in PROCEPT BioRobotics by 46.0% in the fourth quarter. KBC Group NV now owns 2,236 shares of the company's stock valued at $180,000 after buying an additional 705 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th. Bank of America dropped their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Truist Financial reduced their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Finally, Morgan Stanley dropped their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $90.00.

PROCEPT BioRobotics Price Performance

PRCT stock traded up $1.64 during mid-day trading on Wednesday, reaching $61.63. 727,364 shares of the company's stock were exchanged, compared to its average volume of 824,857. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 12-month low of $47.04 and a 12-month high of $103.81. The stock's 50 day moving average is $55.02 and its 200 day moving average is $68.85. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -31.60 and a beta of 1.10.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business's revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.51) EPS. On average, research analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insider Buying and Selling

In related news, CFO Kevin Waters sold 733 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. This represents a 0.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. The trade was a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).